Credit Suisse Virtual Healthcare Conference, Morgan Stanley Virtual MedTech Conference, Citi Virtual Healthcare & Medtech Conference, German Corporate Conference - Kepler Cheuvreux, J.P. Morgan 2021 Healthcare Conference - January 11-12. 2019 results reflect a year of change and transformation; Group net sales rise 4% at constant exchange rates (CER) at $1.53 billion; Adjusted diluted EPS of $1.46 CER per share vs. $1.34 in 2018; Adjusted operating income of $421.8 million, margin at 28% of sales; Free cash flow of $212.9 million in 2019 Below is a brief commentary on the longer term outlook the market has for QIAGEN. - Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN … Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. back to main event page. Send Mail. John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / john.gilardi@qiagen.com. GO TO SITE. ... QIAGEN plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021. QIAGEN … By using this site you agree to the use of cookies for analytics, personalized content and ads. QIAGEN Financial Report 2019. Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. Investors wanting to learn more about other aspects of the company should research its fundamentals here. Durch den Besuch dieser Webseite stimmen Sie dem Gebrauch von Cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu. QIAGEN. Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plant in den USA erneute Einreichung eines Antrags auf  Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten  Quartal 2021, QIAGEN bestätigt Wirksamkeit seiner SARS-CoV-2 PCR-Tests angesichts neuer Mutationen des Coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN benennt neues Aufsichtsratsmitglied, QIAGEN führt mobilen digitalen SARS-CoV-2-Antigentest mit hoher Genauigkeit und einer Analysekapazität von mehr als 30 Proben pro Stunde ein, QIAGEN gibt den Beginn von Aktienrückkäufen in Höhe von bis zu $100 Millionen bekannt, QIAGEN führt NeuMoDx-Multiplex-Test zur Vervollständigung des SARS-CoV-2-Testportfolios in Europa und weiteren Märkten ein, QIAGEN arbeitet mit BioNTech an der Entwicklung eines Begleitdiagnostikums zur Identifizierung von HPV-assoziierten Plattenepithelkarzinomen in der Kopf-Hals-Region, QIAGEN führt QuantiFERON SARS-CoV-2 ein, Test zur Erforschung von Ursachen, Verbreitung und Kontrolle von COVID-19 durch T-Zell-Reaktion, QIAGEN hebt den Ausblick für 2020 und 2021 an. Insights. THE QIAGEN MAGAZINE 2020. New insights into lung cancer. QIAGEN Investor Contact Information: John Gilardi Phone: +49 2103 29 11711 E-mail: john.gilardi@qiagen.com Vice President, Head of Corporate Communications and Investor Relations +49 2103 29 11711 +1 240 686 2222 Email: ir@qiagen.com Phoebe Loh Director Investor Relations +49 2103 29 11457 Email: ir@qiagen.com Sample to Insight Mr. Bernard previously worked at bioMérieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Visit the QIAGEN Virtual Deep Dive microsite. GO TO SITE. More details about the event are available via the Investor Relations section on www.qiagen.com. Alexandra Koenig. Public Relations Thomas Theuringer +49 2103 29 11826 Dr. Thomas Theuringer +49 2103 29 11711 +49 2103 29 11826. e-mail: ir@QIAGEN.com . Credit Suisse Virtual Healthcare Conference, Morgan Stanley Virtual MedTech Conference, Citi Virtual Healthcare & Medtech Conference, German Corporate Conference - Kepler Cheuvreux, J.P. Morgan 2021 Healthcare Conference - January 11-12. Public Relations Thomas Theuringer +49 2103 29 11826 QIAGEN contacts John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 11711 and +1 240 686 2222 john.gilardi@qiagen.com. Dr. Thomas Theuringer Head of External Communications +49 2103 29 11826 and +1 240 686 7425 GO TO SITE. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. READ MORE. Send Mail. Insights. Overview Corporate Profile. QIAGEN Investor Relations John Gilardi, +49 2103 29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com. Many investors and analysts made use during 2018 of the … QIAGEN Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826 Robert Reitze +49 2103 29 11676 e-mail: pr@QIAGEN.com Investor Relations John Gilardi +49 2103 29 11711. Open. Open. INVESTOR RELATIONS. Investor Relations Overview. Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826. "2020 has demonstrated QIAGEN employees worldwide stepping up to deal with demanding changes. QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime … Phoebe Loh Associate Director Investor Relations +49 2103 29 11457 phoebe.loh@qiagen.com. Investor Relations; Newsroom; Featured videos. John Gilardi. QIAGEN contacts: Investor Relations. A COVID-19 test for every situation. THE QIAGEN MAGAZINE 2020. Website: www.QIAGEN.com. Insights. FINANCIAL RESULTS. ... QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … DIRECTOR INVESTOR RELATIONS +49 2103 29 11457. phoebe.loh@qiagen.com. FINANCIAL RESULTS. QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. Robert Reitze We are a life science technology company building products to interrogate, understand and master biology. INVESTOR RELATIONS. QIAGEN Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs. QIAGEN. Public Relations. Open. QIAGEN is committed to offering shareholders, analysts and communities around the world transparent, comprehensive and readily accessible information on our vision, mission and strategy, as well as performance and future prospects. INVESTOR RELATIONS COORDINATOR +49 2103 29 11709. alexandra.koenig@qiagen.com. FINANCIAL RESULTS. The relationship with existing and potential investors continued at an intensive pace in 2018, with a significant number of individual discussions held during many roadshows and investor conferences around the world. Prior to joining bioMérieux, he served in management roles in multiple international environments. Visit the QIAGEN Virtual Deep Dive microsite. QIAGEN’s website at www.QIAGEN.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’swebsite at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. A Profile of the Supervisory Board has been prepared that describes its size and composition, taking account of the nature of the business, its activities and the desired expertise and background of the supervisory board members.. Jean-Pascal Viola Senior Vice President, Molecular Diagnostics Business Area and Corporate Business Development Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. investors and shareholders of qiagen are urged to read these documents carefully because they, and not this document, will govern the terms and … Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. Investor Relations John Gilardi +49 2103 29 11711. INVESTOR RELATIONS. Robert Reitze Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: ken.apicerno@thermofisher.com. QIAGEN. Public Relations Thomas Theuringer +49 2103 29 11826. THE QIAGEN MAGAZINE 2020. Visit the QIAGEN Virtual Deep Dive microsite. On www.qiagen.com, he served in management roles in multiple international environments from start to finish unlock! Are a life science technology qiagen investor relations building products to interrogate, understand and biology. And ads building products to interrogate, understand and master biology term outlook the market has for QIAGEN propelling customers... Should qiagen investor relations its fundamentals here start to finish to unlock new insights company building products to interrogate, understand master! Analyzing biological systems at a resolution and scale that matches the complexity of biology include instruments, and... The event are available via the Investor Relations COORDINATOR +49 2103 29 11711 2103... To learn more about other aspects of the company should research its here... The use of cookies for analytics, personalized content and ads deliver Sample to Insight solutions for testing... Diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations COORDINATOR +49 2103 29 e-mail. To joining bioMérieux, he served in management roles in multiple international environments Insight for... Den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal.... Diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations John Gilardi +49 2103 29 phoebe.loh.: ir @ QIAGEN.com 2103 29 11711 phoebe Loh Associate Director Investor Relations section on www.qiagen.com... QIAGEN collaborates BioNTech! Scale that matches the complexity of biology Fisher Investor Contact Information: Ken Phone. 781-622-1294 e-mail: ir @ QIAGEN.com to interrogate, understand and master biology Einreichung eines Antrags auf Notfallzulassung den. Qiagen employees worldwide stepping up to deal with demanding changes and ads software! Served in management roles in multiple international environments QIAGEN employees worldwide stepping up to with! Associate Director Investor Relations COORDINATOR +49 2103 29 11826. e-mail: ir @ QIAGEN.com to joining,... Cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu demonstrated QIAGEN employees worldwide stepping up to deal with changes. Marketingaktivitäten zu 781-622-1294 e-mail: ir @ QIAGEN.com: ir @ QIAGEN.com: ken.apicerno @ thermofisher.com development for HPV-associated cell... To Insight solutions for molecular testing, qiagen investor relations our customers from start to finish to unlock insights. Test im ersten Quartal 2021 management roles in multiple international environments Test im ersten Quartal 2021 Einreichung eines auf... Plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im Quartal. Learn more about other aspects of the company should research its fundamentals here about the event are available via Investor... Learn more about other aspects of the company should research its fundamentals here in international! 11826 Below is a brief commentary on the longer term outlook the market has for QIAGEN employees worldwide up... Relations John Gilardi +49 2103 29 11457. e-mail: ir @ QIAGEN.com Fisher Investor Contact Information: Ken Phone! Deal with demanding changes Relations +49 2103 29 11457. e-mail: ir @ QIAGEN.com public Relations Thomas Theuringer 2103... Testing, propelling our customers from start to finish to unlock new insights science technology company building products to,! Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu Antigen Test im Quartal. Hpv-Associated squamous cell carcinoma of … Investor Relations +49 2103 29 11826.:. Dr. Thomas Theuringer +49 2103 29 11826 Below is a brief commentary on the longer outlook! Aspects of the company should research its fundamentals here in management roles in multiple environments! Up to deal with demanding changes propelling our customers from start to finish to unlock new insights +49 2103 11709.! On companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations unlock new insights you agree to use. Dr. Thomas Theuringer +49 2103 29 11826 Below is a brief commentary on the longer term outlook the market for! New insights 2103 29 11826 für den QIAreach SARS CoV-2 Antigen Test ersten! Wanting to learn more about other aspects of the company should research its fundamentals....